目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 33)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 BIOMARKERS MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 37)
2.1 RESEARCH APPROACH
FIGURE 2 GLOBAL MARKET: RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Primary sources
2.1.2.3 Breakdown of primaries
FIGURE 3 GLOBAL MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 GLOBAL MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF ALL BIOMARKER PRODUCTS IN THE MARKET
FIGURE 7 KEY INDUSTRY INSIGHTS
FIGURE 8 GLOBAL MARKET: CAGR PROJECTIONS, 2023-2028
FIGURE 9 GLOBAL MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH LIMITATIONS
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY (Page No. - 51)
FIGURE 11 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 12 GLOBAL MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 13 GLOBAL MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 14 GLOBAL MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET

4 PREMIUM INSIGHTS (Page No. - 55)
4.1 GLOBAL MARKET OVERVIEW
FIGURE 16 GROWING IMPORTANCE OF COMPANION DIAGNOSTICS EXPECTED TO DRIVE GLOBAL MARKET
4.2 ASIA PACIFIC: GLOBAL MARKET, BY PRODUCT & SERVICE AND BY COUNTRY (2022)
FIGURE 17 CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022
4.3 GLOBAL MARKET, BY REGION, 2022
FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 58)
5.1 MARKET DYNAMICS
FIGURE 19 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.1.1 MARKET DRIVERS
5.1.1.1 Growing importance of companion diagnostics
5.1.1.2 Increase in global prevalence of cancer
TABLE 2 NUMBER OF NEW CANCER CASES, BY TYPE, 2020-2040
TABLE 3 CANCER INCIDENCE, BY REGION (2040)
5.1.1.3 Increase in funds and grants for biomarker research
5.1.1.4 Continuous product innovations
TABLE 4 PRODUCT LAUNCHES, 2020−2022
5.1.2 RESTRAINTS
5.1.2.1 High capital investments and lengthy timelines for biomarker development
TABLE 5 TIME FRAME FOR BIOMARKER DEVELOPMENT
5.1.3 OPPORTUNITIES
5.1.3.1 Personalized medicine
5.1.3.2 Emerging economies
5.1.4 CHALLENGES
5.1.4.1 Challenges associated with biomarker validation
5.1.4.2 Technical issues related to sample collection and storage
5.2 REGULATORY ASSESSMENT
5.2.1 INTRODUCTION
5.2.2 BIOMARKER QUALIFICATION IN US
5.2.3 BIOMARKER QUALIFICATION IN EUROPE
5.3 VALUE CHAIN ANALYSIS
FIGURE 20 GLOBAL MARKET: VALUE CHAIN ANALYSIS
5.4 TECHNOLOGICAL ANALYSIS
5.4.1 IMMUNOASSAYS
5.4.1.1 Immunohistochemistry (IHC)
5.4.1.2 Flow cytometry
5.4.1.3 Flow cytometry ELISA
5.4.2 NEXT-GENERATION SEQUENCING (NGS)
5.4.3 POLYMERASE CHAIN REACTION (PCR)
5.4.4 IN SITU HYBRIDIZATION
5.4.5 MICROARRAYS
5.4.6 MASS SPECTROMETRY
5.5 PRICING ANALYSIS
TABLE 6 SELLING PRICE OF BIOMARKERS BY TOP PLAYERS
5.6 PATENT ANALYSIS
FIGURE 21 PATENT APPLICATIONS FOR GLOBAL MARKET, JANUARY 2012-DECEMBER 2022
5.7 GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 22 GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
5.7.1 KEY INFLUENCERS
5.8 ECOSYSTEM ANALYSIS
TABLE 7 GLOBAL MARKET: SUPPLY CHAIN ECOSYSTEM
5.9 KEY CONFERENCES AND EVENTS, 2023-2024
TABLE 8 GLOBAL MARKET: LIST OF CONFERENCES AND EVENTS
5.10 PORTER’S FIVE FORCES ANALYSIS
5.10.1 IMPACT OF PORTER’S FIVE FORCES ON GLOBAL MARKET
5.10.2 INTENSITY OF COMPETITIVE RIVALRY
5.10.3 BARGAINING POWER OF SUPPLIERS
5.10.4 BARGAINING POWER OF BUYERS
5.10.5 THREAT OF SUBSTITUTES
5.10.6 THREAT OF NEW ENTRANTS
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKERS
5.11.2 GLOBAL MARKET: BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR END USERS
5.12 ECOSYSTEM ANALYSIS OF GLOBAL MARKET
FIGURE 25 GLOBAL MARKET: ECOSYSTEM ANALYSIS
5.12.1 ROLE IN ECOSYSTEM
5.13 REVENUE SHIFT FOR GLOBAL MARKET
FIGURE 26 GLOBAL MARKET: REVENUE SHIFT

6 BIOMARKERS MARKET, BY PRODUCT & SERVICE (Page No. - 82)
6.1 INTRODUCTION
TABLE 9 GLOBAL MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
6.2 CONSUMABLES
6.2.1 NEED FOR HIGH-FREQUENCY PURCHASE OF CONSUMABLES TO DRIVE MARKET GROWTH
TABLE 10 BIOMARKER CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 11 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 12 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 13 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 14 ROW: BIOMARKER CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION)
6.3 SERVICES
6.3.1 GRADUAL SHIFT FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING OF SERVICES TO SUPPORT MARKET GROWTH
TABLE 15 BIOMARKER SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 16 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 17 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 18 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 19 ROW: BIOMARKER SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
6.4 SOFTWARE
6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO SUPPORT MARKET GROWTH
TABLE 20 BIOMARKER SOFTWARE MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 21 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 22 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 24 ROW: BIOMARKER SOFTWARE MARKET, BY REGION, 2021-2028 (USD MILLION)

7 BIOMARKERS MARKET, BY TYPE (Page No. - 90)
7.1 INTRODUCTION
TABLE 25 GLOBAL MARKET, BY TYPE, 2021-2028 (USD MILLION)
7.2 EFFICACY BIOMARKERS
TABLE 26 EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 27 EFFICACY BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 28 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 29 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 31 ROW: MARKET, BY REGION, 2021-2028 (USD MILLION)
7.2.1 PREDICTIVE BIOMARKERS
7.2.1.1 Wide applications of predictive biomarkers in personalized medicine and companion diagnostics to drive market
TABLE 32 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 33 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 34 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 35 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 36 ROW: MARKET, BY REGION, 2021-2028 (USD MILLION)
7.2.2 SURROGATE BIOMARKERS
7.2.2.1 Use of surrogate biomarkers helps accelerate drug development and shorten timelines for regulatory approval
TABLE 37 SURROGATE BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 38 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 39 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 40 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 41 ROW: MARKET, BY REGION, 2021-2028 (USD MILLION)
7.2.3 PHARMACODYNAMIC BIOMARKERS
7.2.3.1 Increasing utilization of pharmacodynamic biomarkers in selection and optimization of drug doses to boost market
TABLE 42 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 43 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 44 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 46 ROW: MARKET, BY REGION, 2021-2028 (USD MILLION)
7.2.4 PROGNOSTIC BIOMARKERS
7.2.4.1 Prognostic biomarkers help predict recurrence of diseases
TABLE 47 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 48 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 49 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 50 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 51 ROW: MARKET, BY REGION, 2021-2028 (USD MILLION)
7.3 SAFETY BIOMARKERS
7.3.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT TO FUEL MARKET GROWTH
TABLE 52 SAFETY BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 53 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 54 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 56 ROW: MARKET, BY REGION, 2021-2028 (USD MILLION)
7.4 VALIDATION BIOMARKERS
7.4.1 VALIDATION BIOMARKERS ENABLE EVALUATION OF DIAGNOSTIC SYSTEMS
TABLE 57 VALIDATION BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 58 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 59 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 60 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 61 ROW: MARKET, BY REGION, 2021-2028 (USD MILLION)

8 BIOMARKERS MARKET, BY DISEASE INDICATION (Page No. - 107)
8.1 INTRODUCTION
TABLE 62 GLOBAL MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
8.2 CANCER
8.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET
TABLE 63 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER
TABLE 64 BIOMARKERS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
TABLE 65 NORTH AMERICA: MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 66 EUROPE: MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 67 ASIA PACIFIC: MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 68 ROW: MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
8.3 INFECTIOUS DISEASES
8.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE DEMAND FOR BIOMARKERS
TABLE 69 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
TABLE 70 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 71 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 72 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 73 ROW: MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
8.4 IMMUNOLOGICAL DISORDERS
8.4.1 INCREASING ADOPTION OF BIOMARKERS FOR VARIOUS IMMUNOLOGICAL DISORDERS TO DRIVE MARKET
TABLE 74 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
TABLE 75 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 76 NORTH AMERICA: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 77 EUROPE: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 78 ASIA PACIFIC: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 79 ROW: MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
8.5 NEUROLOGICAL DISORDERS
8.5.1 IMMUNOASSAYS WIDELY USED IN DIAGNOSIS OF NEUROLOGICAL DISORDERS
TABLE 80 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 81 NORTH AMERICA: MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 82 EUROPE: MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 83 ASIA PACIFIC: MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 84 ROW: MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
8.6 CARDIOVASCULAR DISORDERS
8.6.1 GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS
TABLE 85 BIOMARKERS FOR CARDIOVASCULAR DISORDERS
TABLE 86 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 87 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 88 EUROPE: MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 89 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 90 ROW: MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2021-2028 (USD MILLION)
8.7 OTHER DISEASE INDICATIONS
TABLE 91 BIOMARKERS FOR RENAL DISORDERS
TABLE 92 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021-2028 (USD MILLION)
TABLE 93 NORTH AMERICA: MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 94 EUROPE: MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 96 ROW: MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021-2028 (USD MILLION)

9 BIOMARKERS MARKET, BY APPLICATION (Page No. - 124)
9.1 INTRODUCTION
TABLE 97 GLOBAL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
9.2 DIAGNOSTICS
9.2.1 INCREASING USE OF BIOMARKERS FOR DIAGNOSIS OF VARIOUS DISEASES TO DRIVE GROWTH
TABLE 98 BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 99 NORTH AMERICA: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 100 EUROPE: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 102 ROW: MARKET FOR DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
9.3 DRUG DISCOVERY & DEVELOPMENT
9.3.1 BIOMARKERS PLAY KEY ROLE AS BIOLOGICAL INDICATORS IN DEVELOPMENT OF NEW DRUGS
TABLE 103 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)
TABLE 104 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 105 EUROPE: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 106 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 107 ROW: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
9.4 PERSONALIZED MEDICINE
9.4.1 INCREASING APPLICATIONS OF BIOMARKERS IN PERSONALIZED MEDICINE TO DRIVE MARKET
TABLE 108 SELECTED PERSONALIZED MEDICINE DRUGS AND RELEVANT BIOMARKERS
TABLE 109 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021-2028 (USD MILLION)
TABLE 110 NORTH AMERICA: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 111 EUROPE: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 112 ASIA PACIFIC: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 113 ROW: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
9.5 DISEASE RISK ASSESSMENT
9.5.1 BIOMARKERS WIDELY USED FOR TOXICITY CHARACTERIZATION IN DISEASE DIAGNOSIS AND DRUG DEVELOPMENT PROCESSES
TABLE 114 BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2021-2028 (USD MILLION)
TABLE 115 NORTH AMERICA: MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 116 EUROPE: MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 118 ROW: MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2021-2028 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 119 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
TABLE 120 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 121 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 122 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 123 ROW: MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

10 BIOMARKERS MARKET, BY REGION (Page No. - 137)
10.1 INTRODUCTION
TABLE 124 GLOBAL MARKET, BY REGION, 2021-2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT
TABLE 125 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 126 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 127 NORTH AMERICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 128 NORTH AMERICA: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 129 NORTH AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 130 NORTH AMERICA: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.2.1 US
10.2.1.1 US expected to dominate biomarkers market in North America during forecast period
TABLE 131 US: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 132 US: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 133 US: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 134 US: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 135 US: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing incidence of cancer to drive growth of biomarker research
TABLE 136 CANADA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 137 CANADA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 138 CANADA: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 139 CANADA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 140 CANADA: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.2.3 NORTH AMERICA: RECESSION IMPACT
10.3 EUROPE
TABLE 141 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 142 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 143 EUROPE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 144 EUROPE: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 145 EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 146 EUROPE: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Increase in government funding for biomarker research to drive market growth
TABLE 147 GERMANY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 148 GERMANY: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 149 GERMANY: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 150 GERMANY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 151 GERMANY: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.3.2 UK
10.3.2.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
TABLE 152 UK: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 153 UK: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 154 UK: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 155 UK: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 156 UK: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government investments in genomics and proteomics research to drive market growth
TABLE 157 FRANCE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 158 FRANCE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 159 FRANCE: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 160 FRANCE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 161 FRANCE: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Increasing life science R&D funding to drive market growth
TABLE 162 ITALY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 163 ITALY: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 164 ITALY: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 165 ITALY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 166 ITALY: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Growing focus on cancer biomarkers to propel market growth
TABLE 167 SPAIN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 168 SPAIN: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 169 SPAIN: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 170 SPAIN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 171 SPAIN: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 172 REST OF EUROPE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 173 REST OF EUROPE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 174 REST OF EUROPE: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 175 REST OF EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 176 REST OF EUROPE: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.3.7 EUROPE: RECESSION IMPACT
10.4 ASIA PACIFIC
TABLE 177 ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 178 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 179 ASIA PACIFIC: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 180 ASIA PACIFIC: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 181 ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 182 ASIA PACIFIC: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Increasing burden of diseases and growing focus on development of novel drugs to drive demand for biomarkers
TABLE 183 CHINA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 184 CHINA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 185 CHINA: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 186 CHINA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 187 CHINA: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Strategic collaborations with leading pharmaceutical companies to drive market
TABLE 188 JAPAN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 189 JAPAN: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 190 JAPAN: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 191 JAPAN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 192 JAPAN: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Growing prevalence of target diseases expected to support global market
TABLE 193 INDIA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 194 INDIA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 195 INDIA: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 196 INDIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 197 INDIA: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 198 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 199 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 200 REST OF ASIA PACIFIC: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 201 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 202 REST OF ASIA PACIFIC: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.4.5 ASIA PACIFIC: RECESSION IMPACT
10.5 REST OF THE WORLD
TABLE 203 ROW: BIOMARKERS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 204 ROW: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 205 ROW: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 206 ROW: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 207 ROW: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 208 ROW: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.5.1 LATIN AMERICA
10.5.1.1 Research funding and rising awareness of advanced sequencing technologies to drive market
TABLE 209 LATIN AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 210 LATIN AMERICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 211 LATIN AMERICA: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 212 LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 213 LATIN AMERICA: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.5.2 LATIN AMERICA: RECESSION IMPACT
10.5.3 MIDDLE EAST & AFRICA
10.5.3.1 Increasing focus on proteomics and genomics research to support market growth
TABLE 214 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 215 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 216 MIDDLE EAST & AFRICA: EFFICACY BIOMARKER MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 217 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 218 MIDDLE EAST & AFRICA: MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
10.5.4 MIDDLE EAST & AFRICA: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE (Page No. - 182)
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE28 BIOMARKERS MARKET: STRATEGIES ADOPTED
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE29 REVENUE ANALYSIS OF KEY COMPANIES OVER LAST THREE YEARS (2019-2022)
11.4 MARKET SHARE ANALYSIS
FIGURE30 GLOBAL MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 219 GLOBAL MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
FIGURE31 GLOBAL MARKET: COMPANY EVALUATION MATRIX, 2022
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
11.6.1 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 220 BIOMARKERS MARKET: PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS
11.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 221 GLOBAL MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
11.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES
FIGURE32 GLOBAL MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
11.7.1 PROGRESSIVE COMPANIES
11.7.2 STARTING BLOCKS
11.7.3 RESPONSIVE COMPANIES
11.7.4 DYNAMIC COMPANIES
11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
TABLE 222 GLOBAL MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 223 GLOBAL MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
11.9 COMPETITIVE SCENARIOS AND TRENDS
11.9.1 PRODUCT LAUNCHES
TABLE 224 GLOBAL MARKET: PRODUCT LAUNCHES, JANUARY 2020-DECEMBER 2022
11.9.2 DEALS
TABLE 225 GLOBAL MARKET: DEALS, JANUARY 2020-DECEMBER 2022
11.9.3 EXPANSIONS
TABLE 226 BIOMARKERS MARKET: EXPANSIONS, JANUARY 2020-DECEMBER 2022

12 COMPANY PROFILES (Page No. - 196)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 MERCK KGAA
TABLE 227 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021)
TABLE 228 OTHER DEVELOPMENTS
12.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 229 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
12.1.3 ABBOTT LABORATORIES
TABLE 230 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.4 QIAGEN N.V.
TABLE 231 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 36 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
12.1.5 THERMO FISHER SCIENTIFIC INC.
TABLE 232 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
12.1.6 PERKINELMER, INC.
TABLE 233 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 38 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
12.1.7 BIO-RAD LABORATORIES, INC.
TABLE 234 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
12.1.8 ENZO BIOCHEM, INC.
TABLE 235 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
FIGURE 40 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022)
12.1.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
TABLE 236 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
FIGURE 41 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021)
12.1.10 EUROFINS SCIENTIFIC
TABLE 237 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 42 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
12.1.11 MESO SCALE DIAGNOSTICS, LLC
TABLE 238 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
12.1.12 STRESSMARQ BIOSCIENCES INC.
TABLE 239 STRESSMARQ BIOSCIENCES INC.: BUSINESS OVERVIEW
12.1.13 AGILENT TECHNOLOGIES, INC.
TABLE 240 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
12.1.14 JOHNSON & JOHNSON
TABLE 241 JOHNSON & JOHNSON: BUSINESS OVERVIEW
FIGURE 44 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2021)
12.1.15 DIAMETRA
TABLE 242 DIAMETRA: BUSINESS OVERVIEW
12.1.16 SIGNOSIS, INC.
TABLE 243 SIGNOSIS, INC.: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 SINGULEX, INC.
TABLE 244 SINGULEX, INC.: BUSINESS OVERVIEW
12.2.2 BIOMÉRIEUX SA
TABLE 245 BIOMÉRIEUX SA: BUSINESS OVERVIEW
12.2.3 CISBIO BIOASSAYS
TABLE 246 CISBIO BIOASSAYS: BUSINESS OVERVIEW
12.2.4 EKF DIAGNOSTICS HOLDINGS, PLC
TABLE 247 EKF DIAGNOSTICS HOLDINGS, PLC: BUSINESS OVERVIEW
12.2.5 MICROCONSTANTS, INC.
TABLE 248 MICROCONSTANTS, INC.: BUSINESS OVERVIEW
12.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC.
TABLE 249 NORTHEAST BIOANALYTICAL LABORATORIES LLC.: BUSINESS OVERVIEW
12.2.7 JSR LIFE SCIENCES, LLC
TABLE 250 JSR LIFE SCIENCES, LLC: BUSINESS OVERVIEW
12.2.8 BIOAGILYTIX LABS
TABLE 251 BIOAGILYTIX LABS: BUSINESS OVERVIEW
12.2.9 CELERION
TABLE 252 CELERION: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 249)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS